Redeye initiates coverage of AcouSort, a Swedish medtech company aiming to introduce its unique acoustofluidic technology in the automation of sample preparation process in diagnostics, analytics, and cell therapy manufacturing. Our base case suggests a significant upside potential in the share, and we argue that the main catalysts to close the valuation gap are further progress with its partners and accelerating sales from OEM components.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/